These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19458370)

  • 1. Antiplatelet therapy and vascular-access patency.
    Lok CE
    N Engl J Med; 2009 May; 360(21):2240-2. PubMed ID: 19458370
    [No Abstract]   [Full Text] [Related]  

  • 2. Dipyridamole plus aspirin and hemodialysis graft patency.
    Hentschel DM
    N Engl J Med; 2009 Aug; 361(7):720-1; author reply 721. PubMed ID: 19681176
    [No Abstract]   [Full Text] [Related]  

  • 3. Dipyridamole plus aspirin and hemodialysis graft patency.
    Weale AR; Cooper DG
    N Engl J Med; 2009 Aug; 361(7):720; author reply 721. PubMed ID: 19675337
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of dipyridamole plus aspirin on hemodialysis graft patency.
    Dixon BS; Beck GJ; Vazquez MA; Greenberg A; Delmez JA; Allon M; Dember LM; Himmelfarb J; Gassman JJ; Greene T; Radeva MK; Davidson IJ; Ikizler TA; Braden GL; Fenves AZ; Kaufman JS; Cotton JR; Martin KJ; McNeil JW; Rahman A; Lawson JH; Whiting JF; Hu B; Meyers CM; Kusek JW; Feldman HI;
    N Engl J Med; 2009 May; 360(21):2191-201. PubMed ID: 19458364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CARI guidelines. Pharmacological approaches to preventing vascular access failure.
    Polkinghorne K;
    Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S12-6. PubMed ID: 18713119
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft.
    Nee R; Parker AL; Little DJ; Yuan CM; Himmelfarb J; Lowe SR; Abbott KC
    Clin Nephrol; 2014 Jan; 81(1):38-51. PubMed ID: 24161074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-inhibitory therapy in reconstructive arterial surgery.
    McCollum CN; Goldman M
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():301-9. PubMed ID: 3159216
    [No Abstract]   [Full Text] [Related]  

  • 8. Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.
    Dixon BS; Beck GJ; Dember LM; Depner TA; Gassman JJ; Greene T; Himmelfarb J; Hunsicker LG; Kaufman JS; Lawson JH; Meyers CM; Middleton JP; Radeva M; Schwab SJ; Whiting JF; Feldman HI;
    Clin Trials; 2005; 2(5):400-12. PubMed ID: 16317809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet therapy and patency of saphenous-vein bypass grafts in the legs.
    Conte MS; Belkin M; Donaldson MC; Whittemore AD
    N Engl J Med; 1998 May; 338(19):1387-8. PubMed ID: 9575054
    [No Abstract]   [Full Text] [Related]  

  • 10. [Anticoagulant or antiplatelet aggregation treatment after aortocoronary bypass].
    Sagnol P; Delahaye JP
    Presse Med; 1991 Feb; 20(7):287-90. PubMed ID: 1826353
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antiplatelet drugs and prevention of aortocoronary bypass occlusion].
    Davì G; Botindari G; Catalano I; Strano A
    Cardiologia; 1988 Feb; 33(2):123-6. PubMed ID: 3282656
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiplatelet therapy to prevent coronary artery bypass graft occlusion.
    Buring JE; Hennekens CH
    Circulation; 1990 Sep; 82(3):1046-8. PubMed ID: 2393990
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of platelet inhibitory therapy on prosthetic graft maturation.
    Bearn PE; Moffat C; Seddon AM; Bull H; Marston A; Fox B; McCollum CN
    Int J Exp Pathol; 1993 Feb; 74(1):1-8. PubMed ID: 8471529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis.
    Coleman CI; Tuttle LA; Teevan C; Baker WL; White CM; Reinhart KM
    Int J Clin Pract; 2010 Aug; 64(9):1239-44. PubMed ID: 20455955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exclusive antiplatelet therapy for percutaneous coronary intervention.
    Denardo SJ
    J Am Coll Cardiol; 2009 May; 53(20):1921-2; author reply 922-3. PubMed ID: 19442895
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antiaggregation agents in the prevention of venous graft occlusion in arterial reconstruction].
    Anojcić S; Pavlović S
    Srp Arh Celok Lek; 1989; 117(1-2):73-86. PubMed ID: 2799549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent.
    Zimmermann N; Gams E; Hohlfeld T
    Eur J Cardiothorac Surg; 2008 Jul; 34(1):93-108. PubMed ID: 18448350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
    Milani RV
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S7-S11. PubMed ID: 19213064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of stents in the current era: long-term antiplatelet therapy and late-stent thrombosis.
    Buxton B
    ANZ J Surg; 2008; 78(1-2):2-5. PubMed ID: 18199197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.